Abstract:Abstract Myeloproliferative neoplasms (MPNs) are clonal malignant disorders characterized by the increased production of mature myeloid cells in blood. The classical MPNs include Polycythemia Vera (PV), Essential Thrombocythemia (ET) and Primary Myelofibrosis (PMF). Those pathologies are due to the acquisition of gain-of-function mutations leading to the constitutive activation of the cytokine receptor / JAK2 signaling pathway: JAK2V617F in 70% of cases and mutations in the thrombopoietin receptor (MPL) gene in 5% of cases. More recently, around fifty different mutations in the calreticulin (CALR) gene have been described in 30% of ET and PMF with two more frequent mutations called del52 (type 1) and ins5 (type 2). All the CALR mutations induce a frameshiflt to an alternative reading frame in the exon 9 leading to a new C-term tail of the protein with hydrophobic features, and the loss of the KDEL sequence, which is involved in its endoplasmic reticulum retention. The goal of this work was to understand the role of CALR mutants (del52, del46, del34, ins5, del19, del13) in human hematopoiesis. By studying the variant allele frequency (VAF) in 20 patients, we have shown that the CALR mutations are present in all blood mature cells not only in granulocytes and monocytes (CD14+) with a VAF >30% but also in B cells (CD19+), NK cells (CD56+) and in some cases in T cells (CD3+). Moreover, we have observed that CALR mutations are present in all hematopoietic progenitors including CD34+CD38-CD90+ (HSC), CD34+CD38-CD90- (immature progenitors) and CD34+CD38+ (committed progenitors) cell fractions after investigating the clonal architecture of the progenitors. CALR mutation was detectable in more than 40% of progenitor cells except in 2 patients (15 patients studied) and with, in some cases, no detectable wild type CALR progenitors. Homozygous CALR mutations were rare except in one case associated with disease progression. Whatever the VAF, there was no significant differences among the different progenitor types and granulocytes. Finally, we observed that all the associated mutations studied (TET2, PHF6, SYNE1, SCARA5, PIK3CD, SETD1B) in 6 patients postdated CALR mutations. We could also show in 15 patients samples that CALR mutants give a specific megakaryocytic progenitor (CFU-MK) spontaneous growth mediated both by MPL and JAK2 activation using specific inhibitors and short hairpin RNAs. The CFU-MK spontaneous growth correlated with a constitutive activation of JAK2/STAT3/5 pathway in megakaryocytes derived from in vitro cultures of CD34+ progenitors. In aggregate, these results show that all CALR mutants studied are present in all human hematopoietic cells including myeloid and lymphoid cells, give an early clonal advantage at the level of the HSC compartment and a specific increased growth of the megakaryocytic lineage via MPL/JAK2 activation. Disclosures No relevant conflicts of interest to declare.

Activating mutations in JAK2 and CALR differentially affect intracellular calcium flux in store operated calcium entry

Genetic and Clinical Characteristics of Patients with Philadelphia-Negative Myeloproliferative Neoplasm Carrying Concurrent Mutations in JAK2V617F, CALR, and MPL

Functional Consequence of Protein Kinase A-dependent Phosphorylation of the Cardiac Ryanodine Receptor: Sensitization of Store Overload-Induced Ca2+ Release.

Effects of JAK2 V556F Mutation on the JAK2's Activity, Structural Stability and the Transformation of Ba/F3 Cells.

Neutrophil-specific expression of JAK2-V617F or CALRmut induces distinct inflammatory profiles in myeloproliferative neoplasia

Calreticulin and JAK2V617F driver mutations induce distinct mitotic defects in myeloproliferative neoplasms

Roles of Germline JAK2 Activation Mutation JAK2 V625F in the Pathology of Myeloproliferative Neoplasms

Amino Acid Residue E543 in Jak2 C618r is A Potential Therapeutic Target for Myeloproliferative Disorders Caused by Jak2 C618r Mutation

The Effects of R683S (G) Genetic Mutations on the JAK2 Activity, Structure and Stability.

Deregulation of calcium homeostasis in Bcr-Abl-dependent chronic myeloid leukemia

The Role of Mutated Calreticulin in the Pathogenesis of BCR-ABL1-Negative Myeloproliferative Neoplasms

Progress of CALR Gene Mutation in Myeloproliferative Neoplasm

Molecular basis of JAK2 activation in erythropoietin receptor and pathogenic JAK2 signaling

Calr Vs. JAK2 Vs. MPL Mutations in the Progression of Philadelphia-Negative Myeloproliferative Neoplasms

Roles of T875N Somatic Mutation in the Activity, Structural Stability of JAK2 and the Transformation of OCI-AML3 Cells.

Different impact of calreticulin mutations on human hematopoiesis in myeloproliferative neoplasms

A New Molecular Marker for Myeloproliferative Neoplasms:Calr Mutations

An overview on CALR and CSF3R mutations and a proposal for revision of WHO diagnostic criteria for myeloproliferative neoplasms

New advances in the role of JAK2 V617F mutation in myeloproliferative neoplasms

Calreticulin Mutants Induce an Early Clonal Dominance and a Megakaryocytic Phenotype through the Activation of MPL/JAK2 Pathway in Human Primary Cells

Molecular basis of JAK2 H608Y and H608N mutations in the pathology of acute myeloid leukemia